ReviewMolecules (Basel, Switzerland)2025
Methods for Conjugating Antibodies with Quantum Dots.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Quantum Dot Bioconjugates Enable Order(s)-of-Magnitude Enhancement of Immunoglobulin E Detection Sensitivity.ACS omega · 2026Article
- Lateral Flow Immunochromatographic Assay for Detection of Antibodies Against a Recombinant Human Adenovirus Type 3 Hexon Fragment Using Gold Nanoparticles and Quantum Dots.Diagnostics (Basel, Switzerland) · 2026Article
- Bandgap-Engineered PtAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Silicon quantum dots for neurotheranostic applications in dopamine detection.Journal of nanobiotechnology · 2026Review
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanomaterials are increasingly used in the development of detection systems for various disease biomarkers as tools for reliable early diagnosis, which is a key factor in reducing mortality and increasing treatment effectiveness. The use of quantum dot-antibody conjugates allows for optical detection of various disease markers in biological fluids, tissues, and individual cells with high sensitivity and specificity. The sensitivity and specificity of detection are determined not only by the outstanding optical properties of fluorescent quantum dots but also by the type of antibodies used for binding target analytes and the methods of their conjugation with quantum dots. This review deals with methods of site-specific and site-nonspecific conjugation of quantum dots with antibodies, including full-length and single-domain antibodies, as well as antibody fragments, with a special focus on their structural features and active moieties used for binding to their targets. The review includes examples of successful applications of quantum dot-conjugated antibodies in diagnosis, environment monitoring, and food safety assessment. We also discuss the prospects of further research in this field, including new conjugation methods and issues related to the stability and specificity of probes. The review provides a comprehensive analysis of the current methods and achievements in antibody conjugation from the viewpoint of subsequent analyte detection, highlighting the importance of further research for improving the existing technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.